Guardian Partners Inc. Invests $9.16 Million in Sanofi (NASDAQ:SNY)

Guardian Partners Inc. acquired a new stake in shares of Sanofi (NASDAQ:SNY) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 186,109 shares of the company’s stock, valued at approximately $9,162,000.

Other hedge funds have also added to or reduced their stakes in the company. Synergy Asset Management LLC purchased a new position in Sanofi during the 4th quarter valued at $25,000. McClarren Financial Advisors Inc. increased its position in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the period. Lee Danner & Bass Inc. purchased a new position in Sanofi during the 4th quarter valued at $31,000. Sunbelt Securities Inc. increased its position in Sanofi by 72.1% during the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the period. Finally, Sierra Ocean LLC purchased a new position in Sanofi during the 4th quarter valued at $44,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the stock. The Goldman Sachs Group assumed coverage on shares of Sanofi in a report on Friday. They set a “neutral” rating and a $65.00 target price on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Sanford C. Bernstein upgraded shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Three equities research analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, Sanofi presently has an average rating of “Moderate Buy” and a consensus target price of $62.50.

Sanofi Stock Performance

Shares of Sanofi stock opened at $56.90 on Friday. The stock has a market cap of $144.40 billion, a price-to-earnings ratio of 22.85, a PEG ratio of 1.01 and a beta of 0.58. The firm’s 50-day moving average is $54.55 and its 200 day moving average is $52.89. Sanofi has a 1 year low of $45.22 and a 1 year high of $60.12. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14.

Sanofi (NASDAQ:SNY) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts anticipate that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.